RNS Number : 8839R
Nuformix PLC
05 February 2026
5 February 2026
Nuformix plc
("Nuformix" or the "Company")
Posting of Annual Report and Notice of Annual General Meeting ("AGM")
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 30 September 2025 (the "Annual Financial Report 2025") and the 2026 Notice of AGM are today being posted to its shareholders.
A full pdf version of the Annual Financial Report 2025 together with the Notice of AGM is available for download from the Investor Information section on the Company's website: www.nuformix.com.
The Annual General Meeting will be held at the offices of Arch Law, level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ at 9.30 a.m. on 3 March 2026.
Enquiries:
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAFIFIAFTIEIIR
